Roles of thromboxane and its inhibitor anisodamine in burn shock.
Thromboxane (TXA2) and prostacyclin (PGI2) levels, circulatory platelet aggregate ratios (CPAR), CPK, LDH, GOT, platelet counts, blood viscosity, cortisol and urine epinephrine contents were determined in 42 burned patients who were divided into two groups: Group I control (n = 34) and Group II (n = 8) treated with TXA2 synthesis inhibitor, anisodamine. It was found that in controls, both TXA2 and the TXA2/PGI2 ratio increased significantly. There was no marked difference in PGI2 levels between the two groups. Platelet counts and CPAR decreased, while blood viscosity, CPK, LDH, GOT, cortisol and epinephrine in the controls were all significantly higher than those found in Group II patients. All these findings suggested that the changes of TXA2 and the TXA2/PGI2 ratios played an important role in the haemodynamics and haemorrheology in burn shock. The TXA2 synthesis inhibitor, anisodamine, showed beneficial effects by restoring the haemodynamic and rheological disturbances towards normal by virtue of their ability to induce vascular constriction, platelet aggregation, cellular destruction, destabilization of membranes and release of chemical mediators (including enzymes). Furthermore, at 1-3 days postburn, the levels of CPK, LDH and GOT in controls were higher than those measured at 12 h postburn, but this phenomenon was not marked in the treated group, suggesting that after resuscitation, reperfusion damage had occurred and TXA2 might be responsible for the damage. It is assumed that anisodamine could protect tissues from reperfusion damage. The findings also suggested that anisodamine could quicken the restoration of neuroendocrine disturbance initiated by shock (stress).
Huang
Y S
YS
Burn Institute, Southwestern Hospital, Third Military Medical College of PLA, Chongqing, China.
Li
A
A
Yang
Z C
ZC
D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D002056:Burns / Q000097:blood / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007262:Infusions, Intravenous; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D012769:Shock / Q000097:blood / Q000628:therapy*; D012991:Solanaceous Alkaloids / Q000627:therapeutic use*; D013928:Thromboxane A2 / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use*
D012991:Solanaceous Alkaloids; D014665:Vasodilator Agents; C003922:anisodamine; D013929:Thromboxane B2; D013928:Thromboxane A2; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D006854:Hydrocortisone; D004837:Epinephrine